Numinus Wellness (TSE:NUMI) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Numinus Wellness Inc. has joined forces with Cybin to begin Phase 3 trials of CYB003 for Major Depressive Disorder, marking a major step forward in mental health treatment. The trials, which will start in mid-2024, follow promising Phase 2 results that showed a significant reduction in depression symptoms, leading to an FDA breakthrough therapy designation. This collaboration underscores Numinus’s commitment to advancing mental health care through innovative therapies.
For further insights into TSE:NUMI stock, check out TipRanks’ Stock Analysis page.